John Houston, Ph.D., is a distinguished leader in the biopharmaceutical industry, currently serving as the President and Chief Executive Officer at ARVINAS INC. Dr. Houston's professional journey is marked by his significant contributions to drug discovery and development. He holds a Ph.D. in Biochemistry from the University of Cambridge, where his research focused on protein structure and function. Following his doctoral studies, Dr. Houston honed his skills in various roles at leading pharmaceutical companies, including Bristol-Myers Squibb and Pfizer, where he was instrumental in advancing several drug candidates through clinical trials. At ARVINAS INC., Dr. Houston has been pivotal in steering the company towards its mission of developing novel therapies for cancer and other diseases. Under his leadership, ARVINAS has made remarkable strides in the field of targeted protein degradation, a cutting-edge approach that has the potential to revolutionize treatment paradigms. One of his notable achievements includes overseeing the progression of ARV-471, a promising candidate for breast cancer treatment, into advanced clinical trials. Dr. Houston's strategic vision and commitment to innovation have not only elevated ARVINAS's profile within the industry but have also fostered a culture of scientific excellence and collaboration. In addition to his role at ARVINAS, Dr. Houston is actively involved in the broader scientific community, frequently contributing to academic journals and speaking at international conferences. His dedication to advancing scientific knowledge and improving patient outcomes is evident in his leadership style and the initiatives he champions. Dr. Houston's influence extends beyond ARVINAS, as he serves on several advisory boards and committees focused on biotechnology and healthcare innovation. His multifaceted career and ongoing contributions continue to inspire and drive progress in the biopharmaceutical sector.